J&J's tuberculosis drug Sirturo wins FDA approval

01/1/2013 | Reuters · MSN

The FDA approved the use of Johnson & Johnson's Sirturo, or bedaquiline, in combination with other drugs, to treat patients with multidrug-resistant tuberculosis. Sirturo, developed by J&J's Janssen Therapeutics, is the first new tuberculosis drug to gain approval in 40 years. Because of the possibility of fatal heart problems, Sirturo will carry a boxed warning.

View Full Article in:

Reuters · MSN

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC